The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. It operates through direct ownership, management arrangements, franchising, and the sale of regional developer rights. As of August 9, 2018, the company operated approximately 400 clinics. The company was founded in 2010 and is headquartered in Scottsdale, Arizona.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Patent owners & lessors
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:JYNT
CUSIPN/A
Phone480-245-5960
Debt
Debt-to-Equity Ratio0.75
Current Ratio1.30
Quick Ratio1.30
Price-To-Earnings
Trailing P/E Ratio-33.40
Forward P/E Ratio139.17
P/E GrowthN/A
Sales & Book Value
Annual Sales$25.16 million
Price / Sales4.56
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book23.19
Profitability
EPS (Most Recent Fiscal Year)($0.25)
Net Income$-3,270,000.00
Net Margins-3.72%
Return on Equity-34.99%
Return on Assets-6.02%
Miscellaneous
Employees148
Outstanding Shares13,730,000
Market Cap$118.32 million
Joint (NASDAQ:JYNT) Frequently Asked Questions
What is Joint's stock symbol?
Joint trades on the NASDAQ under the ticker symbol "JYNT."
How were Joint's earnings last quarter?
Joint Corp (NASDAQ:JYNT) announced its earnings results on Thursday, August, 9th. The company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.01. The company earned $7.56 million during the quarter, compared to the consensus estimate of $7.62 million. Joint had a negative return on equity of 34.99% and a negative net margin of 3.72%. View Joint's Earnings History.
When is Joint's next earnings date?
What price target have analysts set for JYNT?
3 equities research analysts have issued 1-year target prices for Joint's shares. Their predictions range from $10.00 to $12.00. On average, they anticipate Joint's stock price to reach $11.00 in the next year. This suggests a possible upside of 31.7% from the stock's current price. View Analyst Price Targets for Joint.
What is the consensus analysts' recommendation for Joint?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Joint in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Joint.
What are Wall Street analysts saying about Joint stock?
Here are some recent quotes from research analysts about Joint stock:
- 1. According to Zacks Investment Research, "The Joint Corp. is a healthcare franchisor of chiropractic clinics. The Company's plans include: Single Visit, Premium Wellness Plan and Wellness Plan. It also provides a family wellness plan. The Company also provides removal of subluxations. It operates its clinics across: Albany, New York; Austin, Texas; Brentwood, California; Fort Mill, South Carolina; Lubbock, Texas; Lynnwood, Washington; Middletown, New Jersey; San Antonio, Texas; San Diego, California and Spartanburg, South Carolina, among others. The Joint Corp. is headquartered in Scottsdale, Arizona. " (8/15/2018)
- 2. Maxim Group analysts commented, "1Q18 revenue of $7.10M, up 28.9% y/y, was relatively inline with both our estimate of $7.18M and consensus of $7.06M.." (5/11/2018)
Who are some of Joint's key competitors?
Some companies that are related to Joint include Quarterhill (QTRH), Acacia Research (ACTG), Liberty Tax (TAX), Finjan (FNJN), Digital Turbine (APPS), ITUS (ITUS), XCel Brands (XELB), Research Frontiers (REFR), MGT Capital Investments (MGTI), Marathon Patent Group (MARA), ARC Group (ARCK), Walker Innovation (WLKR), Spherix (SPEX), XpresSpa Group (XSPA) and Health Discovery (HDVY).
Who are Joint's key executives?
Joint's management team includes the folowing people:
- Mr. Peter D. Holt, CEO, Pres, Interim Principal Financial Officer & Director (Age 59)
- Mr. Jorge Armenteros, VP of Operations
- Dr. James Edwards, Chief Chiropractic & Compliance Officer
- Mr. Craig P. Colmar, Sec. (Age 65)
- Jake Singleton, Corp. Controller
When did Joint IPO?
(JYNT) raised $20 million in an IPO on Tuesday, November 11th 2014. The company issued 3,000,000 shares at $6.50 per share. Roth Capital Partners and Feltl and Company served as the underwriters for the IPO and Sanders Morris Harris was co-manager.
Has Joint been receiving favorable news coverage?
Media stories about JYNT stock have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Joint earned a daily sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future. View Recent Headlines for Joint.
Who are Joint's major shareholders?
Joint's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Sanders Morris Harris LLC (11.06%), Bandera Partners LLC (9.60%), Skylands Capital LLC (4.26%), Nantahala Capital Management LLC (3.94%), Renaissance Technologies LLC (1.92%) and Boston Partners (1.89%). Company insiders that own Joint stock include Bret Sanders, David M Orwasher, Glenhill Advisors Llc, James H Amos Jr, John P Meloun, Peter D Holt and Ronald V Davella. View Institutional Ownership Trends for Joint.
Which institutional investors are selling Joint stock?
JYNT stock was sold by a variety of institutional investors in the last quarter, including Sanders Morris Harris LLC, Skylands Capital LLC, Boston Partners and Russell Investments Group Ltd.. Company insiders that have sold Joint company stock in the last year include John P Meloun and Ronald V Davella. View Insider Buying and Selling for Joint.
Which institutional investors are buying Joint stock?
JYNT stock was bought by a variety of institutional investors in the last quarter, including Bandera Partners LLC, Nantahala Capital Management LLC, Granahan Investment Management Inc. MA, Renaissance Technologies LLC, Acadian Asset Management LLC, Granite Investment Partners LLC, Redmond Asset Management LLC and Macquarie Group Ltd.. Company insiders that have bought Joint stock in the last two years include Bret Sanders, James H Amos Jr, John P Meloun and Peter D Holt. View Insider Buying and Selling for Joint.
How do I buy shares of Joint?
Shares of JYNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Joint's stock price today?
One share of JYNT stock can currently be purchased for approximately $8.35.
How big of a company is Joint?
Joint has a market capitalization of $118.32 million and generates $25.16 million in revenue each year. The company earns $-3,270,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Joint employs 148 workers across the globe.
How can I contact Joint?
Joint's mailing address is 16767 N PERIMETER DRIVE SUITE 240, SCOTTSDALE AZ, 85260. The company can be reached via phone at 480-245-5960 or via email at [email protected]
MarketBeat Community Rating for Joint (NASDAQ JYNT)
MarketBeat's community ratings are surveys of what our community members think about Joint and other stocks. Vote "Outperform" if you believe JYNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe JYNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
